Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma

Arance, A; Berciano-Guerrero, MA; Guo, J; Carlino, MS; Ascierto, PA; Burotto, M; Mortier, L; Queirolo, P; Chiarion-Sileni, V; Schachter, J; Zhang, X; Martin-Liberal, J; Del Vecchio, M; Okpara, CE; Dutcus, C; Zhang, J; Diede, SJ; Neff, T; Long, GV – 2025 – 10.1016/j.annonc.2025.08.008